Delvens published a new research publication on "Antibody Drug Conjugates (ADC) market Insights, to 2030" with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Antibody Drug Conjugates (ADC) market was mainly driven by the increasing R&D spending across the world.
The Antibody Drug Conjugates (ADC) market size was estimated at USD 5.78 billion in 2023 and is projected to reach USD 24.53 billion in 2030 at a CAGR of 22.94% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/antibody-drug-conjugates-adc-market
Antibody-Drug Conjugates (ADCs) are a class of targeted cancer therapies that combine the speciality of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. These therapies are designed to specifically target cancer cells while minimizing damage to healthy cells, which can lead to improved treatment efficacy and reduced side effects compared to traditional chemotherapy.
The Antibody-Drug Conjugates (ADCs) market is expected to grow during the forecast period. This growth can be attributed to the growing prevalence of cancer, the increasing geriatric population and increasing research and development activities for the development of novel therapeutics. However, factors such as stringent government regulations, high cost of procedures and lack of funding are expected to hamper the growth of the market during the forecast period.
North America to Dominate the Market
· North America is estimated to account for the largest market share during the forecast period. In North America, rising cancer cases and technological developments are driving the growth of the market.
· Moreover, increasing approvals from regulatory authorities are expected to drive the growth of the market during the forecast period.
Key Findings
· Based on product type, the market is segmented into adcetris, kadcyla, and other product types. Kadcyla dominated the market in this segment. Kadcyla specifically targets cancer cells that overexpress the HER2 protein, delivering a potent chemotherapy agent directly to the tumor site.
· Based on application, the market is bifurcated into blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and other applications. The breast cancer dominated the market in this segment. This is due to increase in the prevalence of breast cancer all around the world.
· Based on technology, the market is segmented into cleavable linker and non-cleavable linker. The cleavable linker ADCs segment dominated the market in this segment. This is due to their increased efficacy and safety.
· Based on target type, the market is bifurcated into cd30 antibodies, her2 antibodies, other target types. The HER2 target type dominated the ADC market in 2022. This is due to the high prevalence of HER2-positive breast cancer and the availability of multiple ADC products for treating this cancer.
Competitive Landscape
· AbbVie Inc.
· ADC Therapeutics SA
· Antikor-M
· AstraZeneca PLC
· Bristol -Myers Squibb
· Catalent Inc.
· F. Hoffmann-La Roche Ltd
· Genentech Inc.
· ImmunoGen Inc.
· Immunomedics Inc.
· Merck & Co., Inc.
· Mersana Therapeutics Inc.
· Novartis AG
· Oxford BioTherapeutics Ltd
· Pfizer Inc.
· Seagen Inc.
· Sorrento Therapeutics Inc.
· Sterling Pharma Solutions Limited
· Takeda Pharmaceutical Company Ltd and More
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/antibody-drug-conjugates-adc-market
Recent Developments
In Feb 2022, Adcentrx Therapeutics and AvantGen entered a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.
In March 2022, Sanofi and Seagen Inc. entered a collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.
The Antibody Drug Conjugates (ADC) Market is segmented into various segments such as product type, application, technology, target type, end user, and region:
Based on Product Type
· Adcetris
· Kadcyla
· Other Product Types
Based on Application
· Blood Cancer
· Breast Cancer
· Ovary Cancer
· Lung Cancer
· Skin Cancer
· Brain Tumor
· Other Applications
Based on Technology
· Clevable Linker
· Non-cleavable Linker
Based on Target Type
· CD30 Antibodies
· HER2 Antibodies
· Other Target Types
Based on End User
· Hospitals and Speciality Cancer Centers
· Biotechnology and Pharmaceutical Companies
· Other End Users
The Report helps to identify the opportunities in Global Regions:
· North America (the United States, Canada, and Mexico)
· Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
· Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
· South America (Brazil etc.)
· The Middle East and Africa (North Africa and GCC Countries)
Access Full Report: https://www.delvens.com/report/antibody-drug-conjugates-adc-market
In addition to the market data for the Antibody Drug Conjugates (ADC) Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
Frequently Asked Questions
· What are the years considered to study Antibody Drug Conjugates (ADC) Market?
· What is the compound annual growth rate (CAGR) of the Antibody Drug Conjugates (ADC) Market?
· Which region holds the largest market share in Antibody Drug Conjugates (ADC) Market?
· Which region is the fastest growing in Antibody Drug Conjugates (ADC) Market?
· Who are the major players in Antibody Drug Conjugates (ADC) Market?
More Reports from Delvens:
Active Pharmaceutical Ingredient (API) Market size was estimated at USD 165.7 billion in 2023 and is projected to reach USD 241.5 billion in 2030 at a CAGR of 8.1% during the forecast period 2024-2030.
Drug Discovery Market size was estimated at USD 17.3 billion in 2023 and is projected to reach USD 56.8 billion in 2030 at a CAGR of 15.1% during the forecast period 2024-2030.
Electric Ships market size was estimated at USD 5.2 billion in 2023 and is projected to reach USD 12.2 billion in 2030 at a CAGR of 13% during the forecast period 2024-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
